Predictive Precision Proteomics (AP3) Platform Uncovers Need for Dual WEE1/PKMYT1 Inhibition for Superior Single Agent Activity, Leading to the Discovery of ACR-2316
Time: 1:45 pm
day: Day Two
Details:
- Discussing Acrivon’s AP3-based finding that balanced PKMYT1 inhibition overcomes a dominant cellular WEE1 inhibition-induced resistance mechanism resulting in superior single agent activity
- Exploring how Acrivon leveraged its AP3 platform to identify the key signaling nodes associated with maximum on-target activity and guide drug candidate selection
- Analyzing the mechanism of action and potentially class leading potency and selectivity of ACR-2316, translating to superior in vivo efficacy with enhanced therapeutic index compared to single agent WEE1 or PKMYT1 inhibitors
